$1b deal here were come, page-14

maybe the environment / sentiment from big pharma has changed. or something has come into play for benitec that
has enabled a change in strategy. i'm cool with flexible
strategy if the cards are changing.

say they do land a modest deal for a pre clinical that had some useful upfront, if that deal were with a big pharma, then i think the market will value benitec not just on that
deal alone, but also provide some re-evaluation based on it's other prospects. i don't want to speculate how much that re-evaulation could be, but bigger players taking a first look at benitec's other prospective therapy areas will be in for quite a surprise...